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Abstract
Background: Population-based evaluations of programs for prevention of mother-to-child HIV transmission (PMTCT) are
scarce. We measured PMTCT service coverage, regimen use, and HIV-free survival among children #24 mo of age in
Cameroon, Coˆte D’Ivoire, South Africa, and Zambia.
Methods and Findings: We randomly sampled households in 26 communities and offered participation if a child had been
born to a woman living there during the prior 24 mo. We tested consenting mothers with rapid HIV antibody tests and
tested the children of seropositive mothers with HIV DNA PCR or rapid antibody tests. Our primary outcome was 24-mo HIV-
free survival, estimated with survival analysis. In an individual-level analysis, we evaluated the effectiveness of various
PMTCT regimens. In a community-level analysis, we evaluated the relationship between HIV-free survival and community
PMTCT coverage (the proportion of HIV-exposed infants in each community that received any PMTCT intervention during
gestation or breastfeeding). We also compared our community coverage results to those of a contemporaneous study
conducted in the facilities serving each sampled community. Of 7,985 surveyed children under 2 y of age, 1,014 (12.7%)
were HIV-exposed. Of these, 110 (10.9%) were HIV-infected, 851 (83.9%) were HIV-uninfected, and 53 (5.2%) were dead. HIV-
free survival at 24 mo of age among all HIV-exposed children was 79.7% (95% CI: 76.4, 82.6) overall, with the following
country-level estimates: Cameroon (72.6%; 95% CI: 62.3, 80.5), South Africa (77.7%; 95% CI: 72.5, 82.1), Zambia (83.1%; 95%
CI: 78.4, 86.8), and Coˆte D’Ivoire (84.4%; 95% CI: 70.0, 92.2). In adjusted analyses, the risk of death or HIV infection was non-
significantly lower in children whose mothers received a more complex regimen of either two or three antiretroviral drugs
compared to those receiving no prophylaxis (adjusted hazard ratio: 0.60; 95% CI: 0.34, 1.06). Risk of death was not different
for children whose mothers received a more complex regimen compared to those given single-dose nevirapine (adjusted
hazard ratio: 0.88; 95% CI: 0.45, 1.72). Community PMTCT coverage was highest in Cameroon, where 75 of 114 HIV-exposed
infants met criteria for coverage (66%; 95% CI: 56, 74), followed by Zambia (219 of 444, 49%; 95% CI: 45, 54), then South
Africa (152 of 365, 42%; 95% CI: 37, 47), and then Coˆte D’Ivoire (3 of 53, 5.7%; 95% CI: 1.2, 16). In a cluster-level analysis,
community PMTCT coverage was highly correlated with facility PMTCT coverage (Pearson’s r= 0.85), and moderately
correlated with 24-mo HIV-free survival (Pearson’s r= 0.29). In 14 of 16 instances where both the facility and community
samples were large enough for comparison, the facility-based coverage measure exceeded that observed in the community.
Conclusions: HIV-free survival can be estimated with community surveys and should be incorporated into ongoing country
monitoring. Facility-based coverage measures correlate with those derived from community sampling, but may overestimate
population coverage. The more complex regimens recommended by the World Health Organization seem to have
measurable public health benefit at the population level, but power was limited and additional field validation is needed.
Please see later in the article for the Editors’ Summary.
Citation: Stringer JSA, Stinson K, Tih PM, Giganti MJ, Ekouevi DK, et al. (2013) Measuring Coverage in MNCH: Population HIV-Free Survival among Children under
Two Years of Age in Four African Countries. PLoS Med 10(5): e1001424. doi:10.1371/journal.pmed.1001424
Academic Editor: Carla AbouZahr, Independent consultant: Health statistics and policy, Switzerland
Received September 1, 2012; Accepted March 4, 2013; Published May 7, 2013
Copyright:  2013 Stringer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Zambia, South Africa, and Coˆte d’Ivoire work was supported by contract T0906150021 from the US Centers for Disease Control and Prevention
(CDC) Global AIDS Program. The Cameroon work was supported by a grant from The Bill & Melinda Gates Foundation (351-07), which was awarded through the
Elizabeth Glaser Pediatric AIDS Foundation. The CDC was not involved in data collection or management, but through coauthors and the CDC manuscript
clearance process, the CDC was substantially involved in the preparation, review, and approval of the manuscript. The findings and conclusions of this manuscript
are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The Bill & Melinda Gates Foundation was not involved in
the design or conduct of the study, collection, management, analysis, or interpretation of the data, nor was it involved in preparation, review, or approval of the
manuscript. The Elizabeth Glaser Pediatric AIDS Foundation was not involved in data collection, management, or analysis, but through a coauthor was involved in
design of the study, data interpretation, and manuscript preparation, review, and approval.
PLOS Medicine | www.plosmedicine.org 1 May 2013 | Volume 10 | Issue 5 | e1001424
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: ARV, antiretroviral; DHS, Demographic and Health Surveys; HAART, highly active antiretroviral therapy; HR, hazard ratio; IQR, interquartile range; NVP,
nevirapine; PEARL Study, PMTCT Effectiveness in Africa: Research and Linkages to Care Study; PMTCT, prevention of mother-to-child HIV transmission.
* E-mail: jeff_stringer@unc.edu
This paper is part of the PLOS Medicine ‘‘Measuring Coverage in
MNCH’’ Collection.
Introduction
While transmission of HIV from mother to infant has been
virtually eliminated in high-income countries, substantial chal-
lenges remain in low- and middle-income settings, where almost
1,000 children are thought to acquire HIV each day [1–3]. The
efficacy of antiretroviral (ARV) regimens during pregnancy and
postpartum to prevent mother-to-child transmission is well
established, and prevention of mother-to-child transmission
(PMTCT) programs have been implemented in most countries
in Africa [4,5]. However, objective measures of program
effectiveness and public health impact are largely absent from
the refereed literature [6,7]. Despite calls for the virtual
elimination of pediatric HIV, global coverage of PMTCT services
remains far below what will be required to meet such an aggressive
goal [8]. Current ARV guidelines for resource-limited settings
recommend earlier and more effective regimens at higher CD4+
T-lymphocyte thresholds in pregnancy, as well as postpartum
treatment or prophylaxis to the mother or child to prevent
transmission through breastfeeding. More recently, the initiation
of lifelong highly active antiretroviral therapy (HAART) has been
proposed for all pregnant, HIV-infected women [9–11].
The performance of national PMTCT programs is commonly
assessed by aggregating routinely collected service coverage
indicators, which are often incomplete and inaccurate, and
typically lack the site-level nuance needed to drive meaningful
quality improvement efforts [12–14]. Recent service-based eval-
uations have used umbilical cord blood surveillance [15,16] and
infant PCR testing at immunization clinics [17,18] to improve
data quality, but since these methods are facility-based they may
not represent the entire community [6].
Methods
The PMTCT Effectiveness in Africa: Research and Linkages to
Care Study (PEARL Study) was a multi-country evaluation of the
effectiveness of PMTCT services at the community and facility
level. The study’s methodology and facility-based components
have been reported elsewhere [6,15,19–21]. The community
survey component of the study was conducted in 26 communities
in Cameroon, Coˆte D’Ivoire, South Africa, and Zambia between
April 2007 and May 2009.
Household Selection
Each country employed a two-stage sampling technique. The
first stage involved random selection of facilities providing
PMTCT services and has been described in detail elsewhere
[15]. Once the health facilities were selected in the first stage of
sampling, the catchment area of each facility was defined. In all
countries, this was done at the local level by reviewing available
district data and consulting with local staff. In South Africa and
Zambia, we used publically available satellite images (http://www.
google.com/earth); in Cameroon and Coˆte D’Ivoire, we relied
upon local maps. Once the catchment boundaries were defined,
we subdivided each evaluation area by overlaying a grid of 1 km
by 1 km squares. We then estimated the approximate number of
households in each square. If the number of households exceeded
50, the square was further subdivided into four smaller squares. All
squares of at least five households were then ranked in random
order using a ‘‘rank probability proportional to size’’ technique
and were then visited in sequence, with all households in each
successive grid approached until at least 250 households had been
surveyed. In cases where no one was home to participate in the
interview, we made two additional attempts to return, after which
we counted the household as unavailable.
Each country team employed different ways to educate the
communities prior to the surveys, but in each case we met with
local community leaders to introduce the survey. Drama
performances at public markets and targeted radio announcement
were also used. Households were eligible to participate if a child
was born in the home during the 24 mo prior to the study visit
(whether the mother or infant was currently alive or dead). If the
child’s mother was not available for interview, we made up to two
additional attempts to find her. Failing that, or in the case of a
deceased mother, a caregiver was interviewed.
Study Questionnaire
The survey instrument was adapted from the Zambia Demo-
graphic and Health Surveys (DHS) [22] and comprised three
parts. Team members used an eligibility form to enumerate all
living and deceased household members, their sex, and their age.
If there was a child born in the household within the 2 y prior to
the survey, the household was deemed eligible for participation in
the study and informed consent was obtained. The primary survey
respondent was the mother of the eligible child. If the mother was
not available, the child’s primary caregiver was asked to
participate. The maternal questionnaire focused on household
characteristics; demographic information; HIV knowledge, atti-
tudes, and perceptions; and previous obstetrical history. The infant
module covered specific information about the index pregnancy,
including access to and utilization of PMTCT, delivery and
postnatal care, and infant feeding. Teams of at least two members,
including at least one registered nurse, were trained to administer
the survey in local languages at each site.
Specimen Collection and Testing
In all countries we tested all participating HIV-exposed infants
under 24 mo of age for HIV infection. Our procedures for
household testing and results disclosure varied by country. In
Cameroon, mothers and children over 1 y of age were antibody
tested in the household, where pre- and post-test counseling was
performed, and results were provided during the visit. Infant dried
blood spots for HIV PCR testing were not collected from children
whose mothers were seronegative or from those whose mothers
were seropositive, but who were over 12 mo of age, no longer
breastfeeding, and themselves HIV antibody negative. In the other
countries, specimens were obtained from all consenting mothers
and children, with HIV testing performed off-site. In Zambia, we
provided a card with a linked identification number that allowed
participants to access their results (and/or those of their child) at
the local health facility. In South Africa and Coˆte D’Ivoire, test
results were not provided to participants. This was a requirement
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of local ethics review boards, since we were unable to do
confirmatory testing in the home. Women were encouraged to
access routine counseling and testing services if they so desired,
and the study team provided information about where free services
could be accessed. In Zambia, we also offered infant hemoglobin
testing with referral for children found to be anemic.
All countries used the Determine HIV-1 rapid antibody test
(Abbott Laboratories) for initial testing. Confirmatory tests differed
by country. We tested infant dried blood spots for HIV DNA PCR
using Roche Amplicor version 1.5 with manual extraction.
Informed Consent and Ethical Approvals
In each country setting, informed consent was obtained prior to
administering the questionnaire and blood draws. The informed
consent information was customized to suit the procedure and
research ethics requirements in the respective countries. In cases of
participant illiteracy, a non-biased literate witness joined the
informed consent procedure to ensure that objective information
was given about the study and that the patient understood. Ethical
approval was obtained from the institutional review boards at the
University of Alabama at Birmingham (Birmingham, Alabama,
US) and the US Centers for Disease Control and Prevention
(Atlanta, Georgia, US), as well as the local research ethics review
bodies in each of the participating countries.
Analysis
Our primary outcome was HIV-free survival among HIV-
exposed children. Our sample size was chosen to deliver a half-
confidence interval of 5% around the primary outcome in each
country; we assumed a binomial distribution. The actual number
of houses approached per community also took into account
country-specific estimates of maternal HIV seroprevalence and
baseline child survival. Statistical analyses were performed using
SAS statistical software version 9.1.4 (SAS Institute) and R
software version 2.4.1 (http://www.r-project.org). Background
characteristics were described using medians and interquartile
ranges (IQRs) for continuous variables and percentages for
categorical variables. Children were stratified according to their
HIV-exposure status, HIV-status, and mortality. The present
analysis is limited to those children who were known to be exposed
to HIV, either through the detection of HIV antibodies in the
infant him- or herself, or through a positive maternal HIV
diagnosis. HIV-exposed children who were alive and tested HIV
negative by DNA PCR were right-censored at the time of testing
in time-to-event analyses. HIV-infected children were left-
censored at the time of testing, because transmission was known
to have occurred prior to the test date. Twenty-four-month HIV-
free survival was estimated using a Weibull regression model and a
parametric accelerated failure time model with corresponding
95% confidence intervals. Hazard ratios (HRs) for various
covariates of interest were fitted in multivariate Weibull regression
models and were restricted to children with responses for each of
the covariates of interest. Children born in a particular community
or a particular country may be similar to each other. We
accounted for this potential correlation by including a separate
fixed effect variable for both community and country in our
multivariable model. In cases where one mother contributed more
than one child to the analysis (e.g., twin gestation or short birth
interval), we accounted for this correlation by including a
‘‘mother’’ variable as a random effect. To understand the potential
for variable co-linearity, we calculated the variance inflation
factors of all variables included in the multivariate model. The
variance inflation factor for each variable was less than 1.5, which
indicates variable multi-co-linearity is not an issue in our model.
The effect of infant feeding on HIV-free survival was limited to
those children who were at least 6 mo of age.
In a planned secondary analysis, we compared coverage of
PMTCT services at the facility level (‘‘facility PMTCT coverage’’)
to coverage of PMTCT services at the community level
(‘‘community PMTCT coverage’’). We also compared facility
PMTCT coverage to HIV-free survival among HIV-exposed
infants. Facility PMTCT coverage was ascertained through an
anonymous cord blood surveillance exercise that has been
described elsewhere [15]. In the present report, we compare this
facility-based coverage measure to the results of our community
surveys. Community PMTCT coverage is defined as the
proportion of children in our survey born to HIV-positive mothers
in whom any ARV drug is reported to have been used during
pregnancy. We weighted our estimates according to the number of
HIV-exposed infants in a given service cluster and restricted the
analysis to clusters with at least 15 exposed infants.
Results
The household survey was conducted in six areas in Cameroon,
six in Coˆte D’Ivoire, six in South Africa, and eight in Zambia.
Collectively, these areas represent the entire catchment population
of the 43 facilities included in the sampling scheme [15]. Of 28,942
households visited between 16 May 2008 and 20 May 2009, 9,348
(32%) were eligible (Figure 1). In total, 10,236 children had been
born to 9,606 mothers in the previous 2 y. Some children could
not be analyzed: 1,465 (14%) mothers or caregivers refused to
participate in the survey, while 588 (6%) agreed to be interviewed
but refused to provide specimens. In addition, we lost or could not
analyze 198 specimens (2%).
Of 7,985 surveyed and analyzable children under 2 y of age,
1,014 (12.7%) were HIV-exposed. Of these, 110 (10.9%) were
HIV-infected, 851 (83.9%) were HIV-uninfected, and 53 (5.2%)
were dead (Figure 1). Overall response rates—defined as complete
child data available—varied by country, with South Africa having
the lowest (64%), followed by Coˆte D’Ivoire (73%), Zambia (88%),
and Cameroon (90%).
Participant Characteristics
Household characteristics are shown in Table 1. The proportion
of households reporting access to a flush toilet or pit latrine ranged
from 41% in Coˆte D’Ivoire to 98% in Cameroon. More than 60%
of all households in each of the four countries had finished floors
(e.g., cement, tile, or wood). Access to electricity was highest in
South Africa and Coˆte D’Ivoire (95%), and lower in Cameroon
(66%) and Zambia (33%). South Africa had the highest proportion
of households with a refrigerator (75%) and television (81%). The
proportion of homes with mobile phones ranged from 55% in
Zambia to 87% in South Africa.
The median age of women participating in the survey was 25 y
(IQR: 21–30) and the median parity was 2 (IQR: 1–3). With the
exception of South African mothers (43%), the majority of women
were married or cohabiting. Employment was highest in
Cameroon (67%) and lowest in South Africa (20%). In South
Africa 83% of mothers had completed at least secondary level
school, but only 13% had done so in Cameroon (Table 2).
Reported utilization of antenatal and delivery services was high
across all countries (Table 3). More than 90% of women had
attended at least one antenatal visit during their pregnancy with
the index child, and the proportion reporting a facility delivery
ranged from 87% in Coˆte D’Ivoire to 96% in Cameroon. The
median gestational age at which women initiated antenatal care
was 4 mo (IQR: 3–6) in Coˆte D’Ivoire and South Africa and 5 mo
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(IQR: 4–6) in Cameroon and Zambia. The proportion of
respondents who reported having undergone HIV testing during
the index pregnancy was high for Zambia (91%), Cameroon
(93%), and South Africa (94%), but much lower in Coˆte D’Ivoire
(39%). Among women who reported having been tested for HIV
during the index pregnancy, the rates of self-reported HIV-
positivity were significantly lower than the actual HIV seroprev-
alence of mothers from blood collected at the time of the survey
(Coˆte D’Ivoire [0.3% versus 3.9%; p,0.01], Cameroon [4.9%
versus 7.4%; p,0.01], South Africa [9.1% versus 19.8%; p,0.01],
and Zambia [12.6% versus 23.6%; p,0.01]).
The median birth weight of the index pregnancy was similar
across countries (total cohort median 3,100 g; IQR: 2,800–3,500).
Measles vaccination coverage by 10 mo of age ranged between
61% (Coˆte D’Ivoire) and 90% (Cameroon). In Coˆte D’Ivoire,
Cameroon, and Zambia, more than 75% of children more than
6 mo of age were reported to have been exclusively breastfed for
6 mo, while in South Africa, only 40% of children were reported
to have been exclusively breastfed, and mixed feeding was
common (47%). The proportion of HIV-exposed infants in each
country who received no PMTCT prophylaxis at all varied from
48% in Cameroon to 61% in South Africa. The highest
proportion of infants whose mothers received HAART during
pregnancy was found in Coˆte D’Ivoire (46%), followed by 14% in
Zambia, 9% in South Africa, and 4% in Cameroon (Table 2).
HIV-Free Survival
HIV-free survival at 24 mo of age among HIV-exposed
children was 79.7% (95% CI: 76.4, 82.6). These rates differed
by country, but not significantly so: Cameroon (72.6%; 95% CI:
Figure 1. Description of the cohort of children born in the previous 2 y (n=10,236) from all eligible households (n=9,348) visited
from May 2008 to May 2009.
doi:10.1371/journal.pmed.1001424.g001
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62.3, 80.5), South Africa (77.7%; 95% CI: 72.5, 82.1), Zambia
(83.1%; 95% CI: 78.4, 86.8), and Coˆte D’Ivoire (84.4%; 95% CI:
70.0, 92.2) (Figure 2A). HIV-free survival was highest in children
born to mothers who received dual ARV prophylaxis or HAART
(88.5%; 95% CI: 82.4, 92.6), followed by children whose mothers
received single-dose nevirapine (NVP) (82.2%; 95% CI: 73.7,
88.2), followed by children who received no PMTCT intervention
(78.3%; 95% CI: 73.9, 82.0), although these results did not differ
significantly (Figure 2B). In adjusted analyses, risk of death or HIV
infection among children receiving a more complex regimen of
either dual ARV prophylaxis or HAART was lower (adjusted HR:
0.60; 95% CI: 0.34, 1.06; p=0.067), compared to those receiving
no prophylaxis, but not significantly so. In a pairwise comparison
of children receiving a more complex regimen of either dual ARV
prophylaxis or HAART versus those receiving only single-dose
NVP prophylaxis, we did not observe additional benefit (adjusted
HR: 0.88; 95% CI: 0.45, 1.44), but power to detect a difference
was limited. No other parameters studied were associated with
improved HIV-free survival (Table 4).
PMTCT Intervention Coverage
Of 976 HIV-exposed infants in the study for whom complete
laboratory and survey data are available, 449 reportedly received at
least some ARV drug prophylaxis during pregnancy or the
postnatal period. This represents an unadjusted community
PMTCT coverage of 46% (95% CI: 43, 49). Community PMTCT
coverage differed significantly by country. It was highest in
Cameroon, where 75 of 114 HIV-exposed infants met criteria for
coverage (66%; 95% CI: 56, 74), followed by Zambia (219 of 444,
49%; 95%CI: 45, 54), then South Africa (152 of 365, 42%; 95%CI:
37, 47), and then Coˆte D’Ivoire (3 of 53, 5.7%; 95% CI: 1.2, 16).
In a cluster-level analysis limited to the 16 facility–community
pairs that had at least 15 HIV-exposed infants, we found
community PMTCT coverage to be highly correlated with
facility PMTCT coverage [15] (Pearson’s correlation coefficient
r= 0.85). In every instance except for two, the facility-based
coverage measure exceeded that observed in the community
(Table 5; Figure 3A). While community PMTCT coverage was
moderately correlated with HIV-free survival (r=0.29;
Figure 3B), we did not observe an association between facility
PMTCT coverage and community HIV-free survival (r=0.02;
Figure 3C).
Discussion
The PEARL Study community survey sampled representative
households in four African countries to estimate 24-mo HIV-free
survival among HIV-exposed children. Despite high reported HIV
testing rates and utilization of delivery services, overall community
PMTCT coverage was low, with less than half of HIV-exposed
infants having received any ARV prophylaxis during gestation or
the postnatal period. We think there is an important lesson to be
learned in comparing the previously reported facility-based
coverage estimates [15] to the community-based estimates
Table 1. Characteristics of households surveyed with a child under 2 y of age in the PEARL Study.
Characteristic Coˆte D’Ivoire Cameroon Zambia South Africa Total
N Value N Value N Value N Value N Value
Participation in survey 1,682 1,579 (93.9%) 2,425 2,403 (99.1%) 2,302 2,089 (90.7%) 2,939 1,924 (65.5%) 9,348 7,995 (85.6%)
Water supply to household 1,561 2,385 2,083 1,915 7,944
Piped water into house 409 (26.2%) 97 (4.1%) 305 (14.6%) 762 (39.8%) 1,573 (19.8%)
Piped water outside but available within plot 749 (48.0%) 302 (12.7%) 279 (13.4%) 937 (48.9%) 2,267 (28.5%)
Public tap 130 (8.3%) 1,472 (61.7%) 488 (23.4%) 177 (9.2%) 2,267 (28.5%)
Other 273 (17.5%) 514 (21.6%) 1,011 (48.5%) 39 (2.0%) 1,837 (23.1%)
Toilet facilities in household 1,556 2,394 2,086 1,921 7,957
Flush toilet or pit latrine 637 (40.9%) 2,352 (98.2%) 1,844 (88.4%) 1,577 (82.1%) 6,410 (80.6%)
No facility 919 (59.1%) 42 (1.8%) 242 (11.6%) 344 (17.9%) 1,547 (19.4%)
Does your household have electricity? 1,566 2,400 2,086 1,924 7,976
Yes 1,491 (95.2%) 1,597 (66.5%) 685 (32.8%) 1,826 (94.9%) 5,599 (70.2%)
No 75 (4.8%) 803 (33.5%) 1,401 (67.2%) 98 (5.1%) 2,377 (29.8%)
Does your household have a refrigerator? 1,563 2,398 2,085 1,923 7,969
Yes 303 (19.4%) 296 (12.3%) 458 (22.0%) 1,444 (75.1%) 2,501 (31.4%)
No 1,260 (80.6%) 2,102 (87.7%) 1,627 (78.0%) 479 (24.9%) 5,468 (68.6%)
Main material of floor 1,557 2,351 2,055 1,917 7,880
Finished floor (cement/tiles/wood planks) 1,375 (88.3%) 1,593 (67.8%) 1,257 (61.2%) 1,675 (87.4%) 5,900 (74.9%)
Natural floor (earth/mud/dung/sand) 182 (11.7%) 758 (32.2%) 798 (38.8%) 242 (12.6%) 1,980 (25.1%)
Does your household have a television? 1,564 2,396 2,059 1,914 7,933
Yes 1,188 (76.0%) 1,243 (51.9%) 797 (38.7%) 1,558 (81.4%) 4,786 (60.3%)
No 376 (24.0%) 1,153 (48.1%) 1,262 (61.3%) 356 (18.6%) 3,147 (39.7%)
Does your household have a cell phone? 1,563 2,393 2,075 1,912 7,943
Yes 1,205 (77.1%) 1,583 (66.2%) 1,139 (54.9%) 1,664 (87.0%) 5,591 (70.4%)
No 358 (22.9%) 810 (33.8%) 936 (45.1%) 248 (13.0%) 2,352 (29.6%)
doi:10.1371/journal.pmed.1001424.t001
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reported here.While the estimates correlate highly (r=0.85), we found
the facility-based coverage estimate to be higher than the community-
based coverage estimate in every facility–community pair except for
two (Figure 3A). This suggests to us that the facility population can be
thought of as a subset of the community, and a coverage estimate
derived from it will be valid only in settings where most patients come
to the facility for services. There are mother–infant pairs in the
community who are simply not sampled by a facility-based estimate,
and, not surprisingly, the PMTCT coverage rates among these
women were generally lower. This finding is consistent with the
observed associations between the two PMTCT coverage estimates
and HIV-free survival (Figure 3B and 3C). While there is a moderate
association between community PMTCT coverage and HIV-free
survival, the association weakens considerably when the coverage
estimate is derived from the facility population only.
The risk of death was lower among children using a potent
ARV regime for PMTCT, but due to limited power, the
association was not significant. An effect of drug potency is
suggested by a dose response in the adjusted analysis and in
Figure 2B. While this phenomenon has been known for some time
in the controlled environment of clinical trials, its demonstration at
the population level provides support for World Health Organi-
zation recommendations to implement more complex PMTCT
ARV regimens on a wide scale.
In aggregate, we think our findings suggest a critical role for
both facility- and community-based monitoring of PMTCT
programs. The facility-based estimates—particularly those capable
of recreating the PMTCT ‘‘cascade’’ [15,17]—can provide
important, practical information about how to best improve
service delivery at the site level. Facility-based estimates are also
easier to obtain, and are thus suited for more routine performance
monitoring. Since some patients do not interact with the
healthcare system at the level of the facility, however, periodic
evaluation of community PMTCT coverage must also be
considered. This aspect of monitoring is most useful when
utilization of facility-based services is low, but is also subject to
bias if sampling is not random. In our study, for instance, we used
random sampling, but excluded those sites and communities
known not to have any PMTCT services at all. Thus, both our
facility and community samples are optimistic representations.
We observed an overall rate of HIV-free survival that was
higher than anticipated by our original modeling [6]. This could
Table 2. Characteristics of mothers surveyed with a child under 2 y of age in the PEARL Study.
Characteristic Coˆte D’Ivoire Cameroon Zambia South Africa Total
N Value N Value N Value N Value N Value
Participation in survey 1,869 1,751 (93.7%) 2,451 2,423 (98.9%) 2,347 2,116 (90.2%) 2,939 2,029 (69.0%) 9,606 8,319 (86.6%)
Caregiver interviewed instead of mother 1,731 2 (0.1%) 2,412 25 (1.0%) 2,110 18 (0.9%) 2,013 121 (6.0%) 8,266 166 (2.0%)
Age at time of survey (median [IQR]) 1,730 26 (21, 30) 2,404 25 (22, 30) 2,112 25 (21, 31) 2,026 25 (21, 32) 8,272 25 (21, 30)
12–19 y 227 (13.1%) 276 (11.5%) 285 (13.5%) 312 (15.4%) 1,100 (13.3%)
20–29 y 995 (57.5%) 1,487 (61.9%) 1,211 (57.4%) 1,074 (53.0%) 4,767 (57.6%)
30+ y 508 (29.4%) 639 (26.6%) 615 (29.1%) 640 (31.6%) 2,402 (29.0%)
Parity (median [IQR]) 1,558 2 (1, 3) 2,394 2 (1, 3) 2,084 2 (1, 4) 1,918 2 (1, 3) 7,954 2 (1, 3)
1 638 (40.9%) 812 (33.9%) 681 (32.7%) 861 (44.9%) 2,992 (37.6%)
2 500 (32.1%) 575 (24.0%) 461 (22.1%) 534 (27.8%) 2,070 (26.0%)
3+ 420 (27.0%) 1,007 (42.1%) 942 (45.2%) 523 (27.3%) 2,892 (36.4%)
Marital status 1,726 2,414 2,103 2,019 8,262
Married/cohabitating 1,513 (87.7%) 1,878 (77.8%) 1,655 (78.7%) 870 (43.1%) 5,916 (71.6%)
Other 213 (12.3%) 536 (22.2%) 448 (21.3%) 1,149 (56.9%) 2,346 (28.4%)
Education 1,723 2,401 2,100 2,019 8,243
Secondary or higher 221 (12.8%) 980 (40.8%) 872 (41.5%) 1,682 (83.3%) 3,755 (45.6%)
No schooling or primary 1,502 (87.2%) 1,421 (59.2%) 1,228 (58.5%) 337 (16.7%) 4,488 (54.4%)
Mother currently employed 1,562 2,393 2,071 1,921 7,947
Yes 640 (41.0%) 1,600 (66.9%) 1,136 (54.9%) 372 (19.4%) 3,748 (47.2%)
No 922 (59.0%) 793 (33.1%) 935 (45.1%) 1,549 (80.6%) 4,199 (52.8%)
Maternal HIV status (lab data) 1,325 2,247 1,968 1,917 7,457
Positive 52 (3.9%) 167 (7.4%) 464 (23.6%) 379 (19.8%) 1,062 (14.2%)
Negative 1,265 (95.5%) 2,076 (92.4%) 1,499 (76.2%) 1,515 (79.0%) 6,355 (85.2%)
Mother dead 8 (0.6%) 4 (0.2%) 5 (0.3%) 23 (1.2%) 40 (0.5%)
PMTCT regimen 48 160 450 363 1,021
None 25 (52.1%) 77 (48.1%) 240 (53.3%) 222 (61.2%) 564 (55.2%)
NVP only 1 (2.1%) 37 (23.1%) 48 (10.7%) 62 (17.1%) 148 (14.5%)
NVP+zidovudine 0 (0.0%) 40 (25.0%) 98 (21.8%) 46 (12.7%) 184 (18.0%)
HAART 22 (45.8%) 6 (3.8%) 64 (14.2%) 33 (9.1%) 125 (12.2%)
Data are number (percent) unless otherwise indicated.
doi:10.1371/journal.pmed.1001424.t002
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be explained by at least three sources of bias. First, all infant deaths
in the communities may not have been identified in the survey.
While every attempt was made to ensure complete ascertainment,
including use of census enumerators from the local community
and study instruments that queried child deaths in multiple ways,
we cannot be certain that all deaths were captured. Second,
because we chose to sample only those communities that had at
least some access to PMTCT services, the included clusters may
have not been representative of the population as a whole. Since
better-resourced facilities will be the first to implement PMTCT
services, our sampled patients may have had access to better
services than others in their respective countries. This suspicion is
supported by the finding that over 85% of respondents reported
having delivered at a facility, which is higher than we expected
from national figures [23–26] but which is perhaps explained by
our selection of households based on their proximity to particular
health facilities. A third potential bias of our study lies in its
imperfect participant response rates. Although a response rate of
78% is typical for a community-based survey, households where
occupants were not found or refused to participate may have been
systematically different from those that were included. If a
household with a death under 24 mo of age was more likely to
refuse entry to study staff, this could have resulted in overestima-
tion of HIV-free survival, especially if that refusal was more likely
among households affected by HIV.
The questionnaire instruments and sampling methodology for
this study drew heavily on the widely used DHS surveys [22]. The
successful conduct of the PEARL Study, and others of similar
design [27], demonstrates that with relatively minor modification,
the DHS surveys could serve as a platform for widespread
estimation of PMTCT program effectiveness. The most critical
modification would require testing mothers for HIV antibodies (to
ascertain infant HIV exposure) and, for those who are seropositive,
testing their infants for infection. Some countries already perform
HIV testing as part of their DHS surveys, but others do not, and
this modification would have to be planned and resources for its
implementation identified.
Figure 2. HIV-free survival by country and by PMTCT regimen in the PEARL Study. (A) HIV-free survival by country among exposes
children; (B) HIV-free survival by PMTCT regimen among exposed children. AZT, zidovudine.
doi:10.1371/journal.pmed.1001424.g002
Table 4. Adjusted hazard of HIV infection or death among HIV-
exposed children under 2 y of age in the PEARL Study (n=893).
Category Characteristic
Adjusted HR
(95%CI)
Household Toilet facilities in household
Flush toilet or pit latrine 1.0
No facility 1.3 (0.8, 2.1)
Main material of floor
Finished floor (cement/tiles/wood planks) 1.0
Natural floor (earth/mud/dung/sand) 0.9 (0.5, 1.5)
Does your household have a cell phone?
Yes 1.0
No 1.2 (0.8, 1.8)
Mother Age at time of survey (years) 0.98 (0.94, 1.03)
School level
No schooling or primary 1.4 (0.9, 2.2)
Secondary or higher 1.0
Infant PMTCT prophylactic regimen
Zidovudine+NVP or HAART 0.60 (0.34, 1.06)
NVP onlya 0.68 (0.39, 1.19)
None 1.0
Child feeding method during first 6 mo
of life (restricted to children older than
6 mo; n=570)
Exclusive breastfeeding 1.0
Mixed 0.51 (0.19, 1.36)
Formula 0.42 (0.12, 1.44)
Adjusted analyses were restricted to children with responses for each of the
covariates of interest; all models adjust for country effects.
aPairwise comparison of NVP only versus zidovudine+NVP or HAART adjusted
HR: 0.88 (95% CI: 0.45, 1.72).
doi:10.1371/journal.pmed.1001424.t004
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Monitoring PMTCT programs remains a formidable challenge.
Given the continually increasing emphasis on program scale-up,
the unprecedented donor investment in affected countries, and the
recent call by the World Health Organization and others for the
virtual elimination of HIV in children by 2015, it is imperative that
the international research and policy communities agree upon
standard methodologies to measure the effectiveness of programs
over time. Population-based evaluations of PMTCT effectiveness
placed within periodic national health surveys could represent an
important program monitoring resource.
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Editors’ Summary
Background. For a pregnant woman who is HIV-positive,
the discrepancy across the world in outlook for mother and
child is stark. Mother-to-child transmission of HIV during
pregnancy is now less than 1% in many high-income
settings, but occurs much more often in low-income
countries. Three interventions have a major impact on
transmission of HIV to the baby: antiretroviral drugs, mode of
delivery, and type of infant feeding. The latter two are
complex, as the interventions commonly used in high-
income countries (cesarean section if the maternal viral load
is high; exclusive formula feeding) have their own risks in
low-income settings. Minimizing the risks of transmitting HIV
through effective drug regimes therefore becomes particu-
larly important. Monitoring progress on reducing the
incidence of mother-to-child HIV transmission is essential,
but not always easy to achieve.
Why Was This Study Done? A research group led by
Stringer and colleagues recently reported a study from four
countries in Africa: Cameroon, Coˆte D’Ivoire, South Africa,
and Zambia. The study showed that even in the health
facility setting (e.g., hospitals and clinics), only half of infants
whose mothers were HIV-positive received the minimum
recommended drug treatment (one dose of nevirapine
during labor) to prevent HIV transmission. Across the
population of these countries, it is possible that fewer
receive antiretroviral drugs, as the study did not include
women who did not access health facilities. Therefore, the
next stage of the study by this research group, reported
here, involved going into the communities around these
health facilities to find out how many infants under two
years old had been exposed to HIV, whether they had
received drugs to prevent transmission, and what proportion
were alive and not infected with HIV at two years old.
What Did the Researchers Do and Find? The researchers
tested all consenting women who had delivered a baby in the
last two years in the surrounding communities. If the mother
was found to be HIV-positive, then the infant was also tested
for HIV. The researchers then calculated how many of the
infants would be alive at two years and free of HIV infection.
Most mothers (78%) agreed to testing for themselves and
their infants. There were 7,985 children under two years of
age in this study, of whom 13% had been born to an HIV-
positive mother. Less than half (46%) of the HIV-positive
mothers had received any drugs to prevent HIV transmission.
Of the children with HIV-positive mothers, 11% were HIV-
infected, 84% were not infected with HIV, and 5% had died.
Overall, the researchers estimated that around 80% of these
children would be alive at two years without HIV infection.
This proportion differed non-significantly between the four
countries (ranging from 73% to 84%). The researchers found
higher rates of infant survival than they had expected and
knew that they might have missed some infant deaths (e.g.,
if households with infant deaths were less likely to take part
in the study).
The researchers found that their estimates of the proportion
of HIV-positive mothers who received drugs to prevent
transmission were fairly similar between their previous study,
looking at health facilities, and this study of the surrounding
communities. However, in 14 out of 16 comparisons, the
estimate from the community was lower than that from the
facility.
What Do These Findings Mean? This study shows that it
would be possible to estimate how many infants are
surviving free of HIV infection using a study based in the
community, and that these estimates may be more accurate
than those for studies based in health facilities. There are still
a large proportion of HIV-positive mothers who are not
receiving drugs to prevent transmission to the baby. The
authors suggest that using two or three drugs to prevent HIV
may help to reduce transmission.
There are already community surveys conducted in many
low-income countries, but they have not included routine
infant testing for HIV. It is now essential that organizations
providing drugs, money, and infrastructure in this field
consider more accurate means of monitoring incidence of
HIV transmission from mother to infant, particularly at the
community level.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001424.
N The World Health Organization has more information on
mother-to-child transmission of HIV
N The United Nations Children’s Fund has more information
on the status of national PMTCT responses in the most
affected countries
HIV-Free Survival in African Children
PLOS Medicine | www.plosmedicine.org 11 May 2013 | Volume 10 | Issue 5 | e1001424
